Literature DB >> 8011818

Clinical epidemiological study of 171 cases of cryptococcosis.

R Rozenbaum1, A J Gonçalves.   

Abstract

We retrospectively studied 171 patients with cryptococcosis who were divided into three groups according to their associated predisposing conditions (if any): group 1 comprised nonimmunosuppressed patients, group 2 comprised patients with AIDS, and group 3 comprised those patients with other conditions and/or who were users of immunosuppressive drugs. Analysis and correlation of the behavior of the mycosis among the three groups showed differences in the demographic data, clinical forms and manifestations of cryptococcosis, laboratory results, morbidity and mortality rates, and histopathologic aspects. Study of the clinical isolates of Cryptococcus neoformans from 83 patients with cryptococcosis showed that 75 were characterized as C. neoformans variety neoformans and eight as C. neoformans var. gatti. Comparison of the distribution of the gattii and neoformans varieties between the nonimmunosuppressed (group 1) and immunosuppressed (groups 2 and 3) patients showed a significant statistical difference (P < .01).

Entities:  

Mesh:

Year:  1994        PMID: 8011818     DOI: 10.1093/clinids/18.3.369

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  45 in total

Review 1.  HTLV-1 and HIV infections of the central nervous system in tropical areas.

Authors:  P Cabre; D Smadja; A Cabié; C R Newton
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-05       Impact factor: 10.154

2.  Molecular epidemiology of Cryptococcus neoformans in Brazil and the United States: evidence for both local genetic differences and a global clonal population structure.

Authors:  S P Franzot; J S Hamdan; B P Currie; A Casadevall
Journal:  J Clin Microbiol       Date:  1997-09       Impact factor: 5.948

3.  The role of cryptococcal antigen assay in diagnosis and monitoring of cryptococcal meningitis.

Authors:  Spinello Antinori; Anna Radice; Laura Galimberti; Carlo Magni; Marco Fasan; Carlo Parravicini
Journal:  J Clin Microbiol       Date:  2005-11       Impact factor: 5.948

4.  Treatment of cryptococcal meningitis in liver transplantation.

Authors:  A Parisi; P Sacchi; G Filice
Journal:  Infection       Date:  1998 Sep-Oct       Impact factor: 3.553

5.  Susceptibilities of Cryptococcus neoformans strains to platelet binding in vivo and to the fungicidal activity of thrombin-induced platelet microbicidal proteins in vitro.

Authors:  S Nail; R Robert; F Dromer; A Marot-Leblond; J M Senet
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

6.  Human cryptococcosis: relationship of environmental and clinical strains of Cryptococcus neoformans var. neoformans from urban and rural areas.

Authors:  A C N Delgado; H Taguchi; Y Mikami; M Myiajy; M C B Villares; M L Moretti
Journal:  Mycopathologia       Date:  2005-01       Impact factor: 2.574

7.  A prospective descriptive study of cryptococcal meningitis in HIV uninfected patients in Vietnam - high prevalence of Cryptococcus neoformans var grubii in the absence of underlying disease.

Authors:  Tran Th Chau; Nguyen H Mai; Nguyen H Phu; Ho D Nghia; Ly V Chuong; Dinh X Sinh; Van A Duong; Pham T Diep; James I Campbell; Stephen Baker; Tran T Hien; David G Lalloo; Jeremy J Farrar; Jeremy N Day
Journal:  BMC Infect Dis       Date:  2010-07-09       Impact factor: 3.090

Review 8.  Critical care of persons infected with the human immunodeficiency virus.

Authors:  Anuradha Ganesan; Henry Masur
Journal:  Clin Chest Med       Date:  2013-04-08       Impact factor: 2.878

9.  Cryptococcal meningitis: description of 3 cases and estimation of T-cell subsets.

Authors:  Lei Zhu; Rui Huang; Huimin Guo; Jinli Zhang; Chen Dong; Hong Han
Journal:  Indian J Pediatr       Date:  2013-06-18       Impact factor: 1.967

10.  Cryptococcus gattii: An Emerging Cause of Fungal Disease in North America.

Authors:  Ashwin Dixit; Scott F Carroll; Salman T Qureshi
Journal:  Interdiscip Perspect Infect Dis       Date:  2009-05-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.